Main Uses and Applications

Biclar Uno is a prolonged-release formulation containing clarithromycin, a macrolide antibiotic. It is primarily used to treat a variety of bacterial infections caused by susceptible microorganisms. Unlike immediate-release versions, this formulation allows for a gradual release of the active ingredient into the bloodstream.

Respiratory Tract Infections

The medication is frequently indicated for infections affecting both the upper and lower respiratory systems. These include:

• Pharyngitis and Tonsillitis: Inflammation of the throat and tonsils caused by specific bacterial strains.
• Acute Maxillary Sinusitis: Bacterial infection of the sinuses.
• Acute Exacerbation of Chronic Bronchitis: Sudden worsening of long-term airway inflammation.
• Community-Acquired Pneumonia: Lung infections ranging from mild to moderate severity acquired outside of hospital settings.

Skin and Soft Tissue Infections

Biclar Uno is also used to manage mild to moderate infections of the skin and underlying tissues. This includes conditions such as folliculitis, cellulitis, and erysipelas, where bacteria have penetrated the skin barrier.

Therapeutic Benefits

The primary benefit of this medication is its ability to inhibit the growth of bacteria by interfering with their protein synthesis. By stopping the multiplication of the bacteria, the body’s immune system is better able to clear the infection.

Prolonged-Release Mechanism

The "Uno" designation refers to its once-daily administration profile. The prolonged-release technology ensures that:

• Stable Concentrations: The medication maintains a more consistent level of the active substance in the body over a 24-hour period.
• Convenience: The simplified schedule may support better adherence to the full course of treatment, which is essential for the effective resolution of bacterial infections.

Regulatory References

1. NIH MedlinePlus overview of Clarithromycin

Who Can and Cannot Use Biclar Uno?

This section defines the eligibility for using Biclar Uno (Clarithromycin) based strictly on official regulatory prescribing information.

Populations for Whom Use is Contraindicated

Biclar Uno is contraindicated in patients with:

• Known hypersensitivity to clarithromycin, any other macrolide antibiotic, or excipients.
• A history of cholestatic jaundice or hepatic dysfunction associated with prior clarithromycin use.
• A history of congenital or documented acquired QT prolongation or ventricular cardiac arrhythmia (e.g., torsades de pointes).
• Existing hypokalaemia or hypomagnesaemia.
• Severe hepatic failure combined with renal impairment.

Age-Related and Conditional Eligibility

Category	Eligibility Rule
Age (Adult/Adolescent)	The tablet form is indicated for adults and children 12 years and older.
Age (Pediatric)	The tablet form is not recommended for children younger than 12 years.
Renal Impairment	Severe renal impairment (CrCl < 30 mL/min) requires the total daily dosage to be reduced by half.
Hepatic Impairment	Caution is required when administering to patients with existing impaired hepatic function.
Pregnancy/Lactation	Use in pregnancy is not recommended. Safety during breastfeeding is not established.

Biclar Uno (Clarithromycin) interactions are primarily driven by its official classification as a strong inhibitor of the enzyme CYP3A4 and the transporter P-glycoprotein. This documented action significantly increases the plasma concentration of many co-administered medicinal products, which forms the basis for regulatory restrictions.

Officially Contraindicated Combinations

Co-administration with certain drugs is strictly prohibited due to the risk of severe toxicity resulting from increased exposure. These include:

• Pimozide, Cisapride, Astemizole, and Terfenadine are contraindicated due to the risk of QT prolongation and subsequent ventricular arrhythmias.
• The use of Lovastatin and Simvastatin is prohibited because their increased exposure elevates the risk of rhabdomyolysis.
• Ergot alkaloids (e.g., Ergotamine and Dihydroergotamine) are contraindicated as the interaction can result in severe vasospasm and ischemia.
• Lurasidone and Oral Midazolam are also prohibited due to documented high increases in their systemic exposure.

Exposure and Condition-Specific Notes

The plasma concentration of Clarithromycin itself is documented to increase when co-administered with Omeprazole. Conversely, strong CYP3A4 inducers, such as the herbal product St. John's Wort, may reduce Clarithromycin's plasma levels. The contraindication for co-administration with Colchicine is officially limited to patients with pre-existing renal or hepatic impairment. For the immediate-release tablet form, the peak plasma concentration ( C max) is documented to increase when taken with food.

Molecular Mechanism: Inhibiting Bacterial Protein Production

Clarithromycin functions as a precise inhibitor by selectively binding to the 50S ribosomal subunit of the bacterial cell . This interaction physically blocks the exit tunnel used by the ribosome to complete and release essential polypeptide chains. By arresting the process of protein synthesis, the drug stops the bacteria from manufacturing the structural and enzymatic components needed for growth and division, thus establishing a bacteriostatic effect, preventing bacterial cell multiplication.

---

Active Metabolite and Deep Tissue Access

The drug's overall mechanism is supported by its major breakdown product, 14-hydroxyclarithromycin, which is also pharmacologically active and contributes to the inhibitory function. Furthermore, the molecule's lipophilic nature facilitates its passage across host cell membranes and its accumulation in immune cells, such as macrophages. This tissue penetration facilitates the deployment of the mechanism against pathogens residing in intracellular or anatomically protected sites, resulting in continuous growth inhibition.

---

Understanding Mechanistic Limitations

The mechanism's functional binding can be challenged by bacterial resistance pathways. Key limitations arise when bacteria enzymatically modify the 23S ribosomal RNA binding site, structurally reducing the drug's affinity, or when they activate efflux pumps that actively expel the drug from the cell. These molecular counter-mechanisms prevent Clarithromycin from reaching the required intracellular concentration for ribosomal inhibition.

Administration Guidelines

Biclar Uno (Clarithromycin) is primarily used via the oral route as a film-coated tablet, although the drug substance is also officially approved for short-term intravenous (IV) infusion in acute, supervised care settings. The specific dosing schedule is tied to the tablet's formulation. The immediate-release (IR) tablet is typically taken at 250 mg or 500 mg twice daily (every 12 hours). In contrast, the extended-release (ER) formulation, which often uses a single daily dose, is taken as 1000 mg once daily.

---

Timing and Physical Handling

Administration is governed by the need for consistent absorption. The IR tablet may be taken with or without food; however, the ER tablet must be taken with food to ensure its proper release kinetics. Extended-release tablets must be swallowed whole and should not be crushed, broken, or chewed. The typical duration of a treatment course for most acute infections ranges from 6 to 14 days, though it is specified that a minimum course of 10 days be maintained for certain infections, such as streptococcal pharyngitis.

---

Population-Specific Use Rules

Official prescribing information dictates dose modifications for specific physiological conditions. The total daily dosage must be reduced by half for adult patients with severe renal impairment (creatinine clearance less than 30 mL/min). Tablets are generally not indicated for children under 12 years; for pediatric use, a weight-based dose of the oral suspension is the preferred route. Intravenous use is typically limited to a transition period of 2 to 5 days before switching to oral therapy.

Research Evidence / Overview of Studies for Biclar Uno

---

Research Evidence for Acute Respiratory Infections and Associated Conditions

This section summarizes the design of Randomized Controlled Trials (RCTs) and systematic reviews that explored outcomes related to common infections of the lungs, sinuses, and throat, focusing on the study outcomes measured in these key short-term studies. Researchers explored Clarithromycin in studies that included adults with Community-Acquired Pneumonia (CAP) and those experiencing exacerbations of Chronic Obstructive Pulmonary Disease (COPD). The outcomes was observed in these studies included clinical cure or failure rates and measurements of functional status. The general applicability of clinical trial findings is continually being affected by the increasing rates of bacterial antibiotic resistance observed globally.

---

Research Evidence for Helicobacter pylori Eradication

This part will describe the evidence base for Clarithromycin as a component of multi-drug combination therapies that were studied in the context of H. pylori infection, outlining the types of trials and the primary outcomes (such as eradication rates) that researchers examined. Studies show patterns related to varying eradication success rates depending on the specific multi-drug combination. Evidence suggests that the measured eradication rate of Clarithromycin-based regimens appears to be lower in many areas where rising resistance is observed, which has prompted regulatory review of standard treatment protocols. Efficacy is highly dependent on regional bacterial resistance data, meaning results apply only to the populations studied.

---

Long-Term Observational Studies and Follow-up Data

This section summarizes the design and populations involved in extended-duration observational research that has tracked patients for years following a short course of Clarithromycin, particularly studies that focused on measuring outcomes related to cardiovascular events and overall survival. The studies examined long-term outcomes up to ten years after the medication was studied, specifically monitoring outcomes related to all-cause mortality and major cardiovascular events. Because this finding originates from a specific trial and a narrow, high-risk population, the results apply only to the populations studied, and certainty remains low regarding the implications of this finding.

Key Studies & References

1. Disseminated Mycobacterium avium Complex: Adult and Adolescent OIs - NIH Clinical Info Guidelines
2. Clinical experience with clarithromycin for the treatment of respiratory tract infections (Review summarizing multiple RCTs)
3. CLARITHROMYCIN tablets, for oral use - Initial U.S. Approval: 1991 (FDA DailyMed Label)

Common questions about Biclar Uno (FAQ)

---

Q: Can Biclar Uno cause stomach upset or diarrhea?

According to official documents, side effects commonly reported with the use of clarithromycin include those related to the gastrointestinal system, such as abdominal pain, nausea, vomiting, and diarrhea. These common effects are often mild and may lessen as the body adjusts to the medication.

---

Q: What are the most common side effects of Biclar Uno that people report?

Regulatory information indicates that the most frequently reported side effects are related to the gastrointestinal system, which can include abdominal discomfort, nausea, vomiting, and diarrhea. Other common effects include headache and a change in taste.

---

Q: Is it normal to have a metallic taste while taking this medicine?

Yes. Official prescribing information describes a change in taste as a common side effect of the medicine. This is frequently reported by users as having an altered or metallic taste.

---

Q: Does Biclar Uno make you feel dizzy or tired?

The official documentation lists headache as a common side effect. Post-marketing surveillance or other documentation has also noted effects such as dizziness and insomnia (difficulty sleeping).

---

Q: What is the main difference between Biclar Uno and regular Biclar?

The primary distinction is the formulation's release mechanism. The 'Uno' formulation is typically the extended-release (ER) tablet, which is designed to be taken once a day. The regular formulation is the immediate-release tablet, which is generally taken twice a day.

---

Q: What is the purpose of the 'extended-release' formulation of Biclar Uno?

The extended-release formulation is a design intended to deliver the medication over a longer period of time. This design is intended to maintain consistent drug levels and supports a less frequent dosing schedule.

---

Q: How long does it usually take to feel better after starting Biclar Uno?

Pharmacokinetic data indicates that the drug concentration generally reaches a stable level within three to four days. While clinical response varies, it is important to continue taking the medication for the duration specified by the prescriber.

---

Q: Is Biclar Uno ever used for dental infections?

While clarithromycin is indicated for some skin and skin structure infections, official regulatory documents do not list dental infections as one of the primary approved uses.

---

Q: Can Biclar Uno be used for stomach ulcers related to bacteria?

Yes, clarithromycin is officially indicated for the eradication of Helicobacter pylori (a type of bacterium that causes ulcers) when it is used as part of a multi-drug combination regimen.

---

Q: Why is Biclar Uno called 'Uno'?

The term 'Uno' is a brand designation often used in international markets to signify the once-daily (one-per-day) dosing schedule. This name differentiates the extended-release formulation from the standard immediate-release version, which requires twice-daily dosing.

---

Q: Is Biclar Uno used for just one type of infection?

No. Official documents list clarithromycin for the treatment of multiple types of bacterial infections. These include specific infections of the respiratory tract, such as pneumonia, and in combination therapy for H. pylori eradication.

---

Q: What happens if I stop taking Biclar Uno too soon?

Official patient information emphasizes that the entire course of medication should be taken as specified. Stopping treatment early may increase the risk of the original infection returning or contribute to the development of antibiotic resistance.

---

Q: Do I need to change my diet while on Biclar Uno?

The extended-release tablet formulation is specified to be taken with food to support its intended absorption. Beyond this specific requirement for the ER tablet, regulatory documents generally state that there are no specific general food restrictions while using this medicine.

---

Q: Are there specific food items that must be avoided with Biclar Uno?

The extended-release tablet is specified to be taken with food. Regulatory documents do not list common food items to avoid; however, they do caution against using certain strong herbal products, such as St. John’s Wort, as this may reduce the drug's effectiveness.

---

Q: How does Biclar Uno affect the healthy bacteria in the gut?

Like all antibiotics, clarithromycin can change the normal balance of microorganisms in the body. Official warnings note that this change in gut flora has been associated with conditions like severe diarrhea, including Clostridioides difficile-associated diarrhea.

---

Q: Why do doctors prescribe Biclar Uno over other antibiotics sometimes?

Prescribing decisions are based on the drug's characteristics described in regulatory documents. These include the drug's activity against specific types of susceptible bacteria, its effectiveness in certain body tissues, and its role in necessary combination regimens for certain infections.

---

Q: Can I take other antibiotics with Biclar Uno?

Clarithromycin is, in fact, sometimes indicated for use in combination with other anti-infectives. The co-administration of clarithromycin with other antibiotics is subject to evaluation due to the potential for increased side effects or drug-drug interactions.

---

Q: What happens if I miss a dose of Biclar Uno?

Official patient instructions generally advise taking the missed dose as soon as possible once remembered. If it is almost time for your next scheduled dose, it is generally advised to skip the missed dose and continue with the regular schedule.

---

Q: How long does Biclar Uno stay in the body after the last dose?

Pharmacokinetic data suggests that the time it takes for the drug to be eliminated from the body is relatively short. The half-life for the active substance is documented to be approximately 5 to 7 hours for the standard dose. This data indicates the drug is generally eliminated from the body within a few days.

---

Q: What is the age limit for people who can use Biclar Uno?

The tablet form of the medicine is indicated for adults and children 12 years and older. While there is no absolute upper age limit listed, official information notes that older adults may require careful monitoring due to potential underlying health conditions or drug interactions.

---

Q: Are there any known long-term side effects associated with Biclar Uno use?

The FDA has issued warnings based on studies of patients with existing coronary artery disease. These studies suggested a potential for an increased long-term risk of death (all-cause and cardiovascular) up to ten years after completing a clarithromycin course.

---

Q: Does Biclar Uno work on lung infections (pneumonia)?

Yes, official regulatory documents list clarithromycin extended-release tablets as indicated for the treatment of specific mild-to-moderate infections, including community-acquired pneumonia in adults.

Storage and Disposal of Biclar Uno (Clarithromycin Extended-Release Tablets)

Scope Item	Regulatory Requirement
Storage Temperature	Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). Storage must remain below 30 C.
Protection	Must be protected from moisture and light. Avoid storage in areas with excess heat.
Container & Integrity	Keep the medication in the original container and keep the container tightly closed.
Child Safety	Must be stored out of the sight and reach of children.
Disposal	Throw away medicine that is no longer needed or expired. Disposal must follow local requirements and official FDA guidelines for safely discarding unused medicine.

Regulatory documents define the necessary storage environment for Biclar Uno, mandating conditions of controlled room temperature and protection from degrading factors like light and moisture to ensure product stability. Labeling includes specific container and child-safety constraints, requiring the product to be kept tightly closed and out of reach of children. Disposal of any unneeded or expired product must be conducted according to local official requirements.